Get the Daily Brief
Latest Biotech News
Amgen’s $600M California R&D Hub to Fuel Biotech Innovation
Amgen announced a $600 million investment to expand its headquarters in Thousand Oaks, California, establishing a new state-of-the-art research and development center. Construction is scheduled to...
Ionis’ Tryngolza Achieves Landmark Phase 3 Results in Hypertriglyceridemia
Ionis Pharmaceuticals reported positive topline outcomes from two pivotal Phase 3 studies (CORE and CORE2) evaluating olezarsen (Tryngolza) in patients with severe hypertriglyceridemia (sHTG). The...
Novartis and Arrowhead’s $200M CNS Pact Targets Parkinson’s Disease
Novartis inked a $200 million upfront licensing agreement with Arrowhead Pharmaceuticals for a preclinical RNA interference drug designed to silence alpha-synuclein, a protein implicated in...
GenomeWeb Top 40 Biotech Stocks Outperform Market in August
The GenomeWeb Top 40 index of omics and molecular diagnostics firms outpaced broader market benchmarks in August 2025, rising an average 10% compared to 3% for the Dow Jones and 5% for the Nasdaq...
FDA Clears Geneseeq's Comprehensive Genomic Tumor Profiling Test
Geneseeq Technology secured 510(k) clearance from the US FDA for its GeneseeqPrime next-generation sequencing (NGS) tumor profiling assay targeting solid malignancies. The test covers 425...
Royalty Pharma Acquires Amgen’s Lung Cancer Drug Royalties for Up to $950M
Royalty Pharma announced a deal to acquire royalty rights in Imdelltra (tarlatamab-dlle), Amgen’s bispecific T-cell engager for extensive-stage small cell lung cancer (ES-SCLC), from BeOne...
AI-Driven Discovery Yields New Antimicrobials from Venom Proteins
Researchers at the University of Pennsylvania employed artificial intelligence to analyze vast venom protein libraries and discover novel antimicrobial peptides with potent activity against...
FDA Clears Qiagen’s High-Throughput Syndromic Testing System
Qiagen received 510(k) clearance for the QIAstat-Dx Rise Syndromic Testing System, an automated platform capable of processing up to 160 samples per day. The system allows automated cartridge...
Charm Therapeutics Raises $80M to Advance Menin Inhibitor into Clinic
Charm Therapeutics closed an $80 million Series B financing round aimed at advancing its next-generation menin inhibitor into clinical development. Menin inhibitors show promise in acute myeloid...
SeqOne Acquires Congenica to Enhance Genomic Data Interpretation
French genomics software company SeqOne completed the acquisition of UK-based Congenica, combining AI-powered next-generation sequencing analysis with clinical decision support and interpretation...
Ionis Pharmaceuticals’ Olezarsen Slashes Triglycerides and Pancreatitis Risk in Pivotal Trials
Ionis Pharmaceuticals announced positive topline results from pivotal Phase 3 CORE and CORE2 studies demonstrating the efficacy of olezarsen in severe hypertriglyceridemia (sHTG). The therapy...
Strategic Acquisition: SeqOne Merges With Congenica to Enhance Genomic Diagnostics
French genomics software company SeqOne has acquired UK-based Congenica, combining SeqOne's AI-powered next-generation sequencing platform with Congenica's clinical decision support and genome...
Merck Advances Oral PCSK9 Inhibitor, Prepares Regulatory Discussions After Phase 3 Success
Merck & Co. announced a third consecutive phase 3 study win for its oral PCSK9 inhibitor, advancing its CORALreef program for hyperlipidemia treatment. With positive clinical results in broader...
John Maraganore and Clive Meanwell Launch Corsera Health to Combat Cardiovascular Disease
Veteran biotech leaders John Maraganore and Clive Meanwell launched Corsera Health with a mission to prevent cardiovascular disease using a combination of AI-based risk prediction and RNA...
FDA Approves Injectable Alzheimer’s Drug Leqembi for Home Maintenance Dosing
The FDA has approved Leqembi, an injectable form of Eisai and Biogen’s Alzheimer’s drug, permitting weekly maintenance dosing that can be administered at patients’ homes. This regulatory milestone...
Foresight Diagnostics and Roche Settle Patent Dispute With Licensing Agreement
Foresight Diagnostics and Roche Molecular Systems have resolved ongoing litigation related to PhasED-Seq sequencing technology through a limited licensing agreement. The deal grants Roche a...
New FDA Clearance for Qiagen’s High-Throughput Syndromic Testing System QIAstat-DX Rise
Qiagen received FDA 510(k) clearance for the QIAstat-DX Rise Syndromic Testing System, capable of processing up to 160 samples daily with automation features including cartridge loading/unloading...
Advanced Deep Learning Model Pythia Enables Precise Genome Editing Across Cell Types
Researchers have introduced Pythia, a deep learning framework improving the precision of CRISPR–Cas9-mediated genome engineering. Pythia predicts optimal repair templates, enabling more accurate...
Tryngolza Shows Promise in Severe Triglyceride Disease With Significant Clinical Benefit
Ionis Pharmaceuticals announced compelling late-stage data for Tryngolza, an RNA-targeting therapy, which significantly reduced triglyceride levels and acute pancreatitis incidences in patients...
New Noninvasive Colorectal Cancer Test ColoAlert Cleared for UK Market
Mainz Biomed secured UK Medicines and Healthcare Products Regulatory Agency approval for ColoAlert, a PCR-based stool DNA biomarker test for colorectal cancer detection. Following its Swiss...